What Stymen Treats: Main Uses and Benefits

This medication is indicated for vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms, generally helping to manage distressing manifestations of the condition.

The therapeutic area is dedicated to easing chronic, localized discomfort related to the condition, which assists patients with maintaining functional stability during difficult episodes.

---

Alleviating Moderate to Severe Pain During Intercourse

Stymen is commonly used for easing moderate to severe pain experienced during sexual activity (dyspareunia). It is applied in clinical settings marked by heightened patient distress, contributing to support that helps ease the overall burden of Genitourinary Syndrome of Menopause (GSM) and VVA.

Addressing Chronic Symptoms and Supporting Tissue Comfort

The medication is relevant for managing symptom clusters that may become intense or disruptive, such as chronic vaginal dryness, burning, and irritation. It helps improve day-to-day comfort by addressing symptoms related to physical discomfort and tissue thinning, which assists patients with maintaining functional stability during difficult episodes.

“The medication is applied in clinical settings marked by heightened patient distress, contributing to support that helps ease the overall symptom burden.”

---

Quick Fact: Relief for Dyspareunia

Stymen is relevant for easing symptomatic discomfort related to Genitourinary Syndrome of Menopause (GSM), and is often applied when symptoms of atrophy are particularly intense and disruptive. The therapy contributes to improved tissue comfort and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. European Medicines Agency (EMA) overview

Official Eligibility and Non-Eligibility Rules

Stymen (Prasterone) is approved for use only in postmenopausal women. Regulatory documents establish strict population eligibility rules and contraindications that define who can and who must not use this medicine.

Category	Official Regulatory Classification
Populations for whom use is allowed	Postmenopausal women
Populations for whom use is contraindicated	History of breast cancer or other estrogen-dependent tumors; Undiagnosed abnormal genital bleeding; Pregnancy; Lactation; Hypersensitivity to the ingredients.
Age-related eligibility rules	Contraindicated in the pediatric population (children and adolescents). No dose adjustment is required for most older adults (over 65).
Eligibility-related restrictions	Caution is advised for patients with a history of venous thromboembolism (VTE), arterial thromboembolic disease, untreated endometrial hyperplasia, uterine fibroids, or severe hepatic/renal impairment.

The eligibility profile for Stymen is structured by establishing the sole approved population (postmenopausal women) and setting clear absolute exclusions (contraindications) based on hormone-sensitive conditions and reproductive status. Eligibility is further limited by the requirement for medical caution and supervision in individuals with specific comorbidities or organ function restrictions.

Interactions with other medicines and products

Stymen (Prasterone) is a local-acting prohormone delivered as a vaginal insert. Its official interaction profile is defined primarily by its localized metabolism and minimal systemic exposure.

---

Contraindicated Combinations and Systemic Restrictions

Co-administration is restricted in women with a known, past, or suspected history of breast cancer. This is a formal constraint because Prasterone is converted intracellularly into small amounts of estrogens and androgens within the vaginal cells. The resulting estrogen metabolite necessitates aligning the drug's use with established contraindications for exogenous estrogen therapy.

---

Lack of Systemic Interaction Risk

Systemic drug interactions are not expected due to the product’s specific route of administration and localized action. Official regulatory information confirms that interactions involving the cytochrome P450 (CYP) enzyme system or other drug transporters are not anticipated.

Consequently, no mandatory timing requirements for separating the administration of Stymen from systemic medications are documented in the regulatory labels. Furthermore, no dose adjustment is required for patients with hepatic impairment or renal impairment, as the local action minimizes dependence on systemic drug clearance.

Stymen's molecular mechanism involves its classification as a sympathomimetic agent that primarily targets and modulates the catecholamine neurotransmitter systems within the central nervous system. The compound functions as an inhibitor of the dopamine transporter (DAT) and the norepinephrine transporter (NET).

By blocking the reuptake of both dopamine and norepinephrine from the synaptic cleft back into the presynaptic neuron, Stymen increases the concentration and prolongs the residency time of these neurotransmitters in the synaptic space. This increased availability results in enhanced and sustained activation of their respective postsynaptic receptors, specifically the D1-like and D2-like dopamine receptors and the adrenergic receptors (alpha1, alpha2, beta1, beta2). The subsequent intracellular cascade involves the modulation of G protein-coupled receptor signaling, which influences downstream targets such as adenylate cyclase and cAMP levels. This sustained catecholaminergic signaling in various neural circuits leads to an overall system-level physiological modulation characterized by increased functional activity across numerous brain regions.

The usage of the Stymen vaginal insert is defined by a standardized, fixed-dose daily protocol for localized administration. The product is administered exclusively via the intravaginal route as a 6.5 mg insert, a format selected to deliver the Prasterone directly to the target tissue. The official dosing regimen mandates the use of one insert once daily without the need for dose titration or adjustment.

The timing of administration is specified as at bedtime, establishing a consistent daily schedule. Procedurally, the insert can be placed using the provided applicator or a clean finger, ensuring it is inserted as far as comfortably possible for proper localized action. For patients continuing therapy, it is emphasized that treatment should be periodically re-evaluated to confirm the continued necessity and benefits of use, typically at intervals such as every six months.

Concerning missed administration, if a dose is forgotten, the patient should skip that dose if the next scheduled administration is due in less than eight hours; doubling the dose to compensate for the missed dose is not permitted by the official instructions. Furthermore, due to the drug's localized delivery, no dose adjustments are required for elderly women or those with renal or hepatic impairment.

Research Evidence / Overview of Studies for Stymen

The official evidence used to evaluate Stymen (Prasterone) is derived from clinical research, primarily focused on postmenopausal women with symptoms associated with vulvovaginal atrophy (VVA). The core of this evidence comes from short-term, randomized, placebo-controlled trials that studied how symptoms and physical markers changed over a defined time interval.

---

Evidence for use in Moderate to Severe Dyspareunia

The medication was evaluated in studies exploring one of the most bothersome outcomes related to physical discomfort associated with VVA: dyspareunia, or pain during sexual activity. The research examined groups of postmenopausal women with symptoms where intensity was observed as moderate or severe. Studies were set up to compare the experience of women using Stymen against those using an insert containing no active drug (placebo).

In these trials, researchers monitored how patient-reported outcomes related to dyspareunia evolved. These findings describe patterns observed in the studies where participants using Stymen indicated changes in their pain severity score compared to the placebo group after the 12-week study period.

Research on Physiological Markers of Vulvovaginal Atrophy (VVA)

Separate from symptom tracking, researchers examined changes in the physical composition of the vaginal lining cells and the acidity of the vaginal environment. Studies monitored data showing patterns related to the Vaginal Maturation Index (VMI), which tracks the proportion of different cells. The data show patterns related to an observed increase in superficial cells and a measured decrease in parabasal cells compared to the placebo group. Additionally, the research describes changes in the vaginal pH level, reporting a decrease in the pH level.

---

Long-term Studies and Follow-up Duration

While the core evidence comes from trials lasting approximately 12 weeks, the medication was studied for extended use in open-label, non-comparative settings for up to one year (52 weeks).

There is limited information for long-term outcomes from comparative research. Since the follow-up durations were limited in the placebo-controlled trials, long-term effects on patient-reported symptoms are not fully established by direct comparative evidence. The findings primarily describe group patterns, and research provides context but not individual predictions.

Common questions about Stymen (FAQ)

Q: What is the active substance in Stymen?

A: The active substance in Stymen is prasterone, which is chemically known as dehydroepiandrosterone (DHEA). According to the official product information, prasterone is classified as a steroid, and it is the key ingredient responsible for the medicine's effect.

---

Q: What is the recommended storage temperature for Stymen?

A: Regulatory documents state that Stymen should be stored at a temperature below 30°C. The regulatory documents require that the medicine be kept in its original container to protect it from moisture and maintain its stability.

---

Q: How should I dispose of Stymen that is no longer needed or expired?

A: Official information advises against disposing of Stymen through wastewater or household waste. Official information typically recommends returning unneeded medicine to a pharmacist for proper disposal, rather than discarding it in household waste. This protocol helps protect the environment from potential medicinal waste.

---

Q: What happens if I forget to use Stymen as prescribed?

A: According to the official product information, the product information states that a missed dose should be used as soon as the patient remembers. However, if it is already time for the next scheduled dose, the official guidance indicates the missed dose should be skipped. It is advised not to take a double dose to compensate for a forgotten one.

---

Q: Does Stymen contain any lactose?

A: Regulatory documents indicate that Stymen does not contain lactose. Patients with known sensitivities or allergies are advised to consult the official patient information leaflet for the full list of inactive ingredients (excipients).

---

Q: What should I do if I suspect an overdose of Stymen?

A: Official product information advises that if an individual uses more Stymen than recommended, they should seek immediate consultation from a doctor or pharmacist. It is important to seek professional medical advice in the event of a suspected overdose.

How to Store and Dispose of Stymen

Storage Requirements

Regulatory documents stipulate that Stymen must be stored at Controlled Room Temperature (typically 20 mathrmC to 25 mathrmC). It is mandatory to protect the medicine from both moisture and light and to keep the original container tightly closed. Do not refrigerate or freeze the product, as these conditions are prohibited to maintain chemical stability.

Handling and Disposal

Stymen must be stored out of the sight and reach of children. If the product requires reconstitution, the resulting solution must be used within the period specified on the regulatory label (e.g., 24 hours), and any unused portion should be discarded. Do not dispose of expired or unused Stymen in household trash or by flushing it down a toilet or drain. Instead, return the product to a government-authorized collection program, such as a pharmacy take-back scheme, for proper pharmaceutical waste disposal.